Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Auto Parts Stores 2
Gas Utilities 1
The Hot Sectors
Consumer Goods 3
OSIR Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Biosurgery and Therapeutics. The Biosurgery segment develops, manufactures, and distributes biologic products for orthopedic, wound healing, and surgical procedures by harnessing the ability of cells and novel constructs for the body's natural healing. It offers Grafix for application to acute and chronic wounds, including diabetic foot ulcers and burns; and Ovation for use in surgical applications. This segment markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. The Therapeutics segment develops and markets products to treat medical conditions in the inflammatory and cardiovascular disease areas. It offers Prochymal for the treatment of refractory acute graft versus host disease in children. This segment also develops biologic stem cell drug candidates, such as Prochymal that is in clinical trials for various indications, including acute graft versus host disease in pediatric and adult patients, Crohn's disease, and acute myocardial infarction; and Chondrogen for osteoarthritis and cartilage protection. The company has a collaborative agreement with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Osiris Therapeutics, Inc. -- OSIR14 Aug 2014, 8:37 amThe Rosen Law Firm, P.A. announces that it is investigating potential civil securities claims against Osiris Therapeutics, Inc. resulting from allegations that the Co
Osiris Falls despite Narrower Q2 Loss and Higher Revenues - Analyst Blog11 Aug 2014, 11:25 amOsiris Falls despite Narrower Q2 Loss and Higher Revenues - Analyst Blog
Osiris Falls despite Narrower Q2 Loss and Higher Revenues11 Aug 2014, 8:50 amOsiris Therapeutics reported second-quarter 2014 loss of 4 cents per share.
Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter7 Aug 2014, 6:22 am